Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins

Pharmaceutical Biotechnology: Drug Discovery and Clinical Applications

Volumn , Issue , 2012, Pages 337-367

  Zhang, Yi ^a   Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Exposure response correlations; Immunogenicity; Model based drug development; Peptide and protein therapeutics; Pharmacodynamics; Pharmacokinetics

Indexed keywords

EID: 84885541722     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527632909.ch14     Document Type: Chapter

References (114)

1. Visiongain (2009) Biosimilars and Follow-On Biologies Report: The Global Outlook 2009-2024. http://www.visiongain.eom (accessed 8 February 2012)
2. Sehaeht, W. and Thomas, J. (2007) Follow-on Biologies: Intellectual Property and Innovation Issues. A Congressional Researeh Serviee Report for Congress.
3. Rueker, N.L. (2007) Biologies in perspeetiee: Expanded elinieal options amid greater eost serutiny, AARP Publie Poliey Institute.
4. Rader, R.A. (2008) (Re)defining biopharmaeeutieal. Nat. Biotechnol., 26, 743-751.
5. Holford, N.H. and Sheiner, L.B. (1982) Kineties of pharmaeologie response. Pharmacol. Ther., 16, 143-166.
6. Derendorf, H. and Meibohm, B. (1999) Modeling of pharmaeokinetie/pharmaeodynamie (PK/PD) relationships: eoneepts and perspeetives. Pharm. Res., 16, 176-185.
7. Meibohm, B. and Derendorf, H. (1997) Basie eoneepts of pharmaeokinetie/pharmaeodynamie (PK/PD) modelling. Int. J. Clin. Pharmacol. Ther., 35,401-413.
8. Tang, L. and Meibohm, B. (2006) Pharmaeokineties of peptides and proteins, in Pharmacokinetics and Pharmacodynamics of Biotech Drugs (ed. B. Meibohm), Wiley-VCH Verlag GmbH, Weinheim, pp. 17-44.
9. Lesko, L.J. (2007) Paving the eritieal path: how ean elinieal pharmaeology help aehieve the vision? Clin. Pharmacol. Ther., 81,170-177.
10. Meibohm, B. and Derendorf, H. (2002) Pharmacokinetic/pharmacodynamic studies in drug product development. J. Pharm. Sci., 91, 18-31.
11. Suryawanshi, S., Zhang, L., Pfister, M., and Meibohm, B. (2010) The current role of model-based drug development. Expert Opin. Drug Discov., 5, 311-321.
12. Tang, L., Persky, A.M., Hochhaus, G., and Meibohm, B. (2004) Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci., 93, 2184-2204.
13. Herbst, R.S., Kim, E.S., and Harari, P.M. (2001) IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin. Biol. Ther., 1, 719-732.
14. Fasano, A. (1998) Novel approaches for oral delivery of macromolecules. J. Pharm. Sci., 87, 1351-1356.
15. Mahato, R.I., Narang, A.S., Thoma, L., and Miller, D.D. (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst., 20, 153-214.
16. Fridberg, M.J., Hedner, U., Roberts, H.R., and Erhardtsen, E. (2005) A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul. Fibrinolysis, 16, 259-266.
17. Gabrilove, J.L., Cleeland, C.S., Livingston, R.B., Sarokhan, B., Winer, E., and Einhorn, L.H. (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol., 19, 2875-2882.
18. Macdougall, I.C., Roberts, D.E., Coles, G.A., and Williams, J.D. (1991) Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin. Pharmacokinet., 20, 99-113.
19. Handelsman, D.J. and Swerdloff, R.S. (1986) Pharmacokinetics of gonadotropin-releasing hormone and its analogs. Endocr. Rev., 7, 95-105.
20. Periti, P., Mazzei, T., and Mini, E. (2002) Clinical pharmacokinetics of depot leuprorelin. Clin. Pharmacokinet., 41, 485-504.
21. Colburn, W. (1991) Peptide, peptoid, and protein pharmacokinetics/pharmacodynamics, in Petides, Peptoids, and Proteins (eds P. Garzone, W. Colburn, and M. Mokotoff), Harvey Whitney Books, Cincinnati, OH, pp. 94-115.
22. Porter, C.J. and Charman, S.A. (2000) Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci., 89, 297-310.
23. Supersaxo, A., Hein, W.R., and Steffen, H. (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res., 7, 167-169.
24. Supersaxo, A., Hein, W., Gallati, H., and Steffen, H. (1988) Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm. Res., 5, 472-476.
25. Chen, A., Baker, D., and Ferraiolo, B. (1991) Points to consider in correlating bioassays and immunoassays in the quantitation of peptides and proteins, in Petides, Peptoids, and Proteins (eds P. Garzone, W. Colburn, and M. Mokotoff), Harvey Whitney Books, Cincinnati, OH, pp. 54-71.
26. Schomburg, A., Kirchner, H., and Atzpodien, J. (1993) Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy. J. Cancer Res. Clin. Oncol., 119, 745-755.
27. Patton, J.S., Bukar, J.G., and Eldon, M.A. (2004) Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin. Pharmacokinet., 43, 781-801.
28. Skyler, J.S., Weinstock, R.S., Raskin, P., Yale, J.F., Barrett, E., Gerich, J.E., and Gerstein, H.C. (2005) Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care, 28, 1630-1635.
29. Hollander, P.A., Blonde, L., Rowe, R., Mehta, A.E., Milburn, J.L., Hershon, K.S., Chiasson, J.L., and Levin, S.R. (2004) Effieaey and safety of inhaled insulin (exubera) eompared with subeutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, eomparative trial. Diabetes Care, 27, 2356-2362.
30. Kim, D., Mudaliar, S., Chinnapongse, S., Chu, N., Boies, S.M., Davis, T., Perera, A.D., Fishman, R.S., Shapiro, D.A., and Henry, R. (2003) Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subeutaneously injeeted insulin in patients with type 2 diabetes. Diabetes Care, 26, 2842-2847.
31. Cleland, J.L., Daugherty, A., and Mrsny, R. (2001) Emerging protein delivery methods. Curr. Opin. Biotechnol., 12, 212-219.
32. Laube, B.L. (2001) Treating diabetes with aerosolized insulin. Chest, 120, 99S-106S.
33. Zito, S.W. (1997) Pharmaceutical Biotechnology: A Programmed Text, Teehnomie Pub. Co., Laneaster, PA.
34. Lawrenee, D. (2002) Intranasal delivery eould be used to administer drugs direetly to the brain. Lancet, 359, 1674.
35. Liu, X.F., Faweett, J.R., Thorne, R.G., DeFor, T.A., and Frey, W.H. 2nd. (2001) Intranasal administration of insulin-like growth faetor-I bypasses the blood-brain barrier and proteets against foeal eerebral isehemie damage. J. Neurol. Sci., 187, 91-97.
36. Chanson, P., Timsit, J., and Harris, A.G. (1993) Clinieal pharmaeokineties of oetreotide. Therapeutie applieations in patients with pituitary tumours. Clin. Pharmacokinet., 25, 375-391.
37. Mitragotri, S., Blanksehtein, D., and Langer, R. (1995) Ultrasound-mediated transdermal protein delivery. Science, 269, 850-853.
38. Pillai, O. and Panehagnula, R. (2003) Transdermal iontophoresis of insulin. V. Effeet of terpenes. J. Control. Release, 88, 287-296.
39. Kumar, S., Char, H., Patel, S., Piemontese, D., Iqbal, K., Maliek, A.W., Neugrosehel, E., and Behl, C.R. (1992) Effeet of iontophoresis on in vitro skin permeation of an analogue of growth hormone releasing faetor in the hairless guinea pig model. J. Pharm. Sci., 81, 635-639.
40. Chang, S.L., Hofmann, G.A., Zhang, L., Deftos, L.J., and Banga, A.K. (2000) Transdermal iontophoretie delivery of salmon ealeitonin. Int. J. Pharm., 200, 107-113.
41. Suzuki, Y., Iga, K., Yanai, S., Matsumoto, Y., Kawase, M., Fukuda, T., Adaehi, H., Higo, N., and Ogawa, Y. (2001) Iontophoretie pulsatile transdermal delivery of human parathyroid hormone (1-34). J. Pharm. Pharmacol., 53, 1227-1234.
42. Brown, M.B., Traynor, M.J., Martin, G.P., and Akomeah, F.K. (2008) Transdermal drug delivery systems: skin perturbation deviees. Methods Mol. Biol., 437, 119-139.
43. Prausnitz, M.R. (2004) Mieroneedles for transdermal drug delivery. Adv. Drug Deliv. Rev., 56, 581-587.
44. Martanto, W., Davis, S.P., Holiday, N.R., Wang, J., Gill, H.S., and Prausnitz, M.R. (2004) Transdermal delivery of insulin using mieroneedles in vivo. Pharm. Res., 21, 947-952.
45. Shen, W.C. (2003) Oral peptide and protein delivery: unfulfilled promises? Drug Discov. Today, 8, 607-608.
46. Leone-Bay, A., Sato, M., Paton, D., Hunt, A.H., Sarubbi, D., Carozza, M., Chou, J., MeDonough, J., and Baughman, R.A. (2001) Oral delivery of biologieally aetive parathyroid hormone. Pharm. Res., 18, 964-970.
47. Pauletti, G.M., Gangwar, S., Siahaan, T.J., Jeffrey, A., and Borehardt, R.T. (1997) Improvement of oral peptide bioavailability: peptidomimeties and prodrug strategies. Adv. Drug Deliv. Rev., 27, 235-256.
48. Chiang, J., Gloff, C.A., Yoshizawa, C.N., and Williams, G.J. (1993) Pharmaeokineties of reeombinant human interferon-beta ser in healthy volunteers and its effeet on serum neopterin. Pharm. Res., 10, 567-572.
49. Flessner, M.F., Lofthouse, J., and Zakariael, R. (1997) In vivo diffusion of immunoglobulin G in musele: effeets of binding, solute exelusion, and lymphatie removal. Am. J. Physiol., 273, H2783-H2793.
50. Reddy, S.T., Berk, D.A., Jain, R.K., and Swartz, M.A. (2006) A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. J. Appl. Physiol., 101, 1162-1169.
51. Kageyama, S., Yamamoto, H., Nakazawa, H., Matsushita, J., Kouyama, T., Gonsho, A., Ikeda, Y., and Yoshimoto, R. (2002) Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler. Thromb. Vasc. Biol., 22, 187-192.
52. Klitgaard, T., Tabanera y Palacios, R., Boffard, K.D., Iau, P.T., Warren, B., Rizoli, S., Rossaint, R., Kluger, Y., and Riou, B. (2006) Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. Crit. Care., 10, R104.
53. Chow, F.S., Benincosa, L.J., Sheth, S.B., Wilson, D., Davis, C.B., Minthorn, E.A., and Jusko, W.J. (2002) Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin. Pharmacol. Ther., 71, 235-245.
54. Tanswell, P., Modi, N., Combs, D., and Danays, T. (2002) Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin. Pharmacokinet., 41, 1229-1245.
55. Ramakrishnan, R., Cheung, W.K., Wacholtz, M.C., Minton, N., and Jusko, W.J. (2004) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J. Clin. Pharmacol., 44, 991-1002.
56. Zhou, H., Jang, H., Fleischmann, R.M., Bouman-Thio, E., Xu, Z., Marini, J.C., Pendley, C., Jiao, Q., Shankar, G., Marciniak, S.J., et al. (2007) Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J. Clin. Pharmacol., 47, 383-396.
57. Straughn, A.B. (2006) Limitations of noncompartmental pharmacokinetic analysis of biotech drugs, in Pharmacokinetics and Pharmacodynamics of Biotech Drugs (ed. B. Meibohm), Wiley-VCH Verlag GmbH, Weinheim, pp. 181-188.
58. Perrier, D. and Mayersohn, M. (1982) Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J. Pharm. Sci., 71, 372-373.
59. Straughn, A.B. (1982) Model-independent steady-state volume of distribution. J. Pharm. Sci., 71, 597-598.
60. Meibohm, B. and Braeckman, R.A. (2007) Pharmacokinetics and pharmacodynamics of peptides and proteins, in Pharmaceutical Biotechnology: Concepts and Applications (eds D.J.A. Crommelin, R.D. Sindelar, and B. Meibohm), Informa Healthcare, New York, pp. 95-123.
61. Kuwabara, T., Uchimura, T., Kobayashi, H., Kobayashi, S., and Sugiyama, Y. (1995a) Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats. Am. J. Physiol., 269, E1-E9.
62. Toon, S. (1996) The relevance of pharmacokinetics in the development of biotechnology products. Eur. J. Drug Metab. Pharmacokinet., 21, 93-103.
63. Mohler, M., Cook, J., Lewis, D., Moore, J., Sinicropi, D., Championsmith, A., Ferraiolo, B., and Mordenti, J. (1993) Altered pharmacokinetics of recombinant human deoxyribonuclease in rats due to the presence of a binding protein. Drug Metab. Dispos., 21, 71-75.
64. Eppler, S.M., Combs, D.L., Henry, T.D., Lopez, J.J., Ellis, S.G., Yi, J.H., Annex, B.H., McCluskey, E.R., and Zioncheck, T.F. (2002) A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin. Pharmacol. Ther., 72, 20-32.
65. Piscitelli, S.C., Reiss, W.G., Figg, W.D., and Petros, W.P. (1997) Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. Clin. Pharmacokinet., 32, 368-381.
66. Clemmons, D.R., Dehoff, M.L., Busby, W.H., Bayne, M.L., and Caseieri, M.A. (1992) Competition for binding to insulin-like growth faetor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs. Endocrinology, 131, 890-895.
67. Wills, R.J. and Ferraiolo, B.L. (1992) The role of pharmaeokineties in the development of bioteehnologieally derived agents. Clin. Pharmacokinet., 23, 406-414.
68. Taki, Y., Sakane, T., Nadai, T., Sezaki, H., Amidon, G.L., Langguth, P., and Yamashita, S. (1998) First-pass metabolism of peptide drugs in rat perfused liver. J. Pharm. Pharmacol., 50, 1013-1018.
69. Wills, R. (1991) A kinetie/dynamie perspeetive of a peptide and protein: GRF and rHuIFN-alpha-2a, in Petides, Peptoids, and Proteins (eds P. Garzone, W. Colburn, and M. Mokotoff), Harvey Whitney Books, Cineinnati, OH, pp. 117-127.
70. MeMartin, C. (1992) Pharmaeokineties of peptides and proteins: opportunities and ehallenges. Adv. Drug Res., 22, 39-106.
71. Meibohm, B. (2004) Pharmaeokineties of protein-and nueleotide-based drugs, in Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids (ed. R.I. Mahato), CRC Press, Boea Raton, pp. 275-294.
72. Meijer, D. and Ziegler, K. (1993) Biological Barriers to Protein Delivery, Plenum Press, New York.
73. Deen, W.M., Lazzara, M.J., and Myers, B.D. (2001) Struetural determinants of glomerular permeability. Am. J. Physiol. Renal. Physiol., 281, F579-F596.
74. Edwards, A., Daniels, B.S., and Deen, W.M. (1999) Ultrastruetural model for size seleetivity in glomerular filtration. Am. J. Physiol., 276, F892-F902.
75. Maaek, T., Park, C., and Camargo, M. (1985) Renal filtration, transport and metabolism of proteins, in The Kidney: Physiology and Pathophysiology (eds D. Seldin and G. Giebiseh), Raven Press, New York, pp. 1773-1803.
76. Andersen, S., Lambreeht, L., Swan, S., Cutler, D., Radwanski, E., Affrime, M., and Garaud, J. (1999) Disposition of reeombinant human interleukin-10 in subjeets with various degrees of renal funetion. J. Clin. Pharmacol., 39, 1015-1020.
77. Inui, K., Terada, T., Masuda, S., and Saito, H. (2000) Physiologieal and pharmaeologieal implieations of peptide transporters, PEPT1 and PEPT2. Nephrol. Dial. Transplant., 15 (Suppl 6), 11-13.
78. Johnson, V. and Maaek, T. (1977) Renal extraetion, filtration, absorption, and eatabolism of growth hormone. Am. J. Physiol., 233, F185-F196.
79. Krogsgaard Thomsen, M., Friis, C., Sehested Hansen, B., Johansen, P., Esehen, C., Nowak, J., and Poulsen, K. (1994) Studies on the renal kineties of growth hormone (GH) and on the GH reeeptor and related effeets in animals. J. Pediatr. Endocrinol., 7, 93-105.
80. Bu, G., Williams, S., Striekland, D.K., and Sehwartz, A.L. (1992) Low density lipoprotein reeeptor-related protein/alpha 2-maeroglobulin reeeptor is an hepatie reeeptor for tissue-type plasminogen aetivator. Proc. Natl. Acad. Sci. U.S.A., 89, 7427-7431.
81. Smedsrod, B. and Einarsson, M. (1990) Clearanee of tissue plasminogen aetivator by mannose and galaetose reeeptors in the liver. Thromb. Haemost., 63, 60-66.
82. Levy, G. (1994b) Pharmaeologie target-mediated drug disposition. Clin. Pharmacol. Ther., 56, 248-252.
83. Kuwabara, T., Uehimura, T., Takai, K., Kobayashi, H., Kobayashi, S., and Sugiyama, Y. (1995b) Saturable uptake of a reeombinant human granuloeyte eolony-stimulating faetor derivative, nartograstim, by the bone marrow and spleen of rats in vivo. J. Pharmacol. Exp. Ther., 273, 1114-1122.
84. Bauer, R.J., Gibbons, J.A., Bell, D.P., Luo, Z.P., and Young, J.D. (1994) Nonlinear pharmaeokineties of reeombinant human maerophage eolony-stimulating faetor (M-CSF) in rats. J. Pharmacol. Exp. Ther., 268, 152-158.
85. Bartoeei, A., Mastrogiannis, D.S., Migliorati, G., Stoekert, R.J., Wolkoff, A.W., and Stanley, E.R. (1987) Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc. Natl. Acad. Sci. U.S.A., 84, 6179-6183.
86. Roopenian, D.C. and Akilesh, S. (2007) FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol., 7, 715-725.
87. Wang, W., Wang, E.Q., and Balthasar, J.P. (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther., 84, 548-558.
88. Dirks, N.L. and Meibohm, B. (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet., 49, 633-659.
89. Kim, J., Hayton, W.L., Robinson, J.M., and Anderson, C. L. (2007) Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin. Immunol., 122, 146-155.
90. Schellekens, H. (2002) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov., 1, 457-462.
91. Schellekens, H. (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther., 24, 1720-1740. discussion 1719.
92. Schellekens, H. (2008) How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol. Annu. Rev., 14, 191-202.
93. Batra, S.K., Jain, M., Wittel, U.A., Chauhan, S.C., and Colcher, D. (2002) Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr. Opin. Biotechnol., 13, 603-608.
94. Schellekens, H. and Jiskoot, W. (2007) Pharmacokinetics and pharmacodynamics of peptides and proteins, in Pharmaceutical Biotechnology: Concepts and Applications (eds D.J.A. Crommelin, R.D. Sindelar, and B. Meibohm), Informa Healthcare, New York, pp. 125-132.
95. Working, P.K. (1992) Potential effects of antibody induction by protein drugs, in Protein Pharmacokinetics and Metabolism (eds B.L. Ferraiolo, M.A. Mohler, and C.A. Gloff), Plenum Press, New York, pp. 73-92.
96. Graham, M.L. (2003) Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev., 55, 1293-1302.
97. Veronese, F.M. and Caliceti, P. (2006) Custom-tailored pharmacokinetics and pharmacodynamics via chemical modifications of biotech drugs, in Pharmacokinetics and Pharmacodynamics of Boptech Drugs (ed. B. Meibohm), Wiley-VCH Verlag GmbH, Weinheim, pp. 271-294.
98. Tabrizi, M. and Roskos, L.K. (2006) Exposure-reponse relationships for therapeutic biologics, in Pharmacokinetics and Pharmacodynamics of Biotech Drugs (ed. B. Meibohm), Wiley-VCH Verlag GmbH, Weinheim, pp. 295-330.
99. Tabrizi, M.A., Tseng, C.M., and Roskos, L.K. (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today, 11, 81-88.
100. CDER/FDA (2003) Exposure Response Relationships: Guidance for Industry. Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.
101. Levy, G. (1986) Kinetics of drug action: an overview. J. Allergy Clin. Immunol., 78, 754-761.
102. Levy, G. (1994a) Mechanism-based pharmacodynamic modeling. Clin. Pharmacol. Ther., 56, 356-358.
103. Racine-Poon, A., Botta, L., Chang, T.W., Davis, F.M., Gygax, D., Liou, R.S., Rohane, P., Staehelin, T., van Steijn, A.M., and Frank, W. (1997) Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin. Pharmacol. Ther., 62, 675-690.
104. Radwanski, E., Chakraborty, A., Van Wart, S., Huhn, R.D., Cutler, D.L., Affrime, M.B., and Jusko, W.J. (1998) Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm. Res., 15, 1895-1901.
105. Sheiner, L.B., Stanski, D.R., Vozeh, S., Miller, R.D., and Ham, J. (1979) Simultaneous modeling of pharmaeokineties and pharmaeodynamies: applieation to d-tuboeurarine. Clin. Pharmacol. Ther., 25, 358-371.
106. Gibbons, J.A., Haneoek, A.A., Vitt, C.R., Knepper, S., Buekner, S.A., Brune, M.E., Milieie, I., Kerwin, J.F. Jr., Riehter, L.S., Taylor, E.W., et al. (1996) Pharmaeologie eharaeterization of CHIR 2279, an N-substituted glyeine peptoid with high-affinity binding for alpha 1-adrenoeeptors. J. Pharmacol. Exp. Ther., 277, 885-899.
107. Pihoker, C., Kearns, G.L., Freneh, D., and Bowers, C.Y. (1998) Pharmaeokineties and pharmaeodynamies of growth hormonereleasing peptide-2: a phase I study in ehildren. J. Clin. Endocrinol. Metab., 83, 1168-1172.
108. Dayneka, N.L., Garg, V., and Jusko, W.J. (1993) Comparision of four basie models of indireet pharmaeodynamie responses. J. Pharmocokinet. Biopharm., 21, 457-478.
109. Sharma, A. and Jusko, W. (1998) Charaeteristies of indireet pharmaeodynamie models and applieations to elinieal drug responses. Br. J. Clin. Pharmacol., 45, 229-239.
110. Sun, Y.N. and Jusko, W.J. (1999) Role of baseline parameters in determining indireet pharmaeodynamie responses. J. Pharm. Sci., 88, 987-990.
111. Ng, C.M., Stefanieh, E., Anand, B.S., Fielder, P.J., and Vaiekus, L. (2006) Pharmaeokineties/pharmaeodynamies of nondepleting anti-CD4 monoelonal antibody (TRX1) in healthy human volunteers. Pharm. Res., 23, 95-103.
112. Agoram, B., Heatherington, A.C., and Gastonguay, M.R. (2006) Development and evaluation of a population pharmaeokinetie-pharmaeodynamie model of darbepoetin alfa in patients with nonmyeloid malignaneies undergoing multieyele ehemotherapy. AAPS J., 8, E552-E563.
113. Perez-Ruixo, J.J., Kimko, H.C., Chow, A.T., Piotrovsky, V., Krzyzanski, W., and Jusko, W.J. (2005) Population eell life span models for effeets of drugs following indireet meehanisms of aetion. J. Pharmacokinet. Pharmacodyn., 32, 767-793.
114. Zhang, L., Pfister, M., and Meibohm, B. (2008) Coneepts and ehallenges in quantitative pharmaeology and model-based drug development. AAPS J., 10, 552-559.